이상반응 보고
| VAERS ID | 2190478 |
|---|---|
| 성별 | 남성 |
| 나이 | |
| 주 코드 | FR |
| 제약회사 | PFIZER\BIONTECH |
| 로트 번호 | ACB5038 |
| 예방접종 횟수 | 4 |
| 접종일 | 2022-02-11 |
| 발병일 | 2022-02-11 |
| 상태 | 사망 |
증상
- 호흡곤란(Dyspnoea)
- 잘못된 용량 투여(Incorrect dose administered)
- 사출 분수(Ejection fraction)
- 심장사(Cardiac death)
이환 중 질병
Coronary heart disease; Diabetes mellitus (diabetes mell. II); Left ventricular diastolic dysfunction (last left ventr.)
지병
기타 의료
이전 예방접종
알레르기
임상 검사
Test Name: Ejection fraction; Result Unstructured Data: Test Result:8.
21 at 28
증상 상세
acute cardiac death on 15Feb2022; shortness of breath as early as the day after the vaccination; Inappropriate dose of Vaccine administered; This is a spontaneous report received from a non-contactable reporter(s) (Consumer or other non HCP) from the Regulatory Authority-WEB.
Regulatory number: DE-PEI-CADR2022282354.
Other Case identifier(s): DE-CADRPEI-2022282354, DE-PEI-202200086937.
A 81 year-old male patient received bnt162b2 (COMIRNATY), administration date 11Feb2022 (Lot number: ACB5038) as dose 4 (booster), single for covid-19 immunisation.
Relevant medical history included: "Diabetes mellitus" (ongoing), notes: diabetes mell.
II; "Coronary heart disease" (ongoing); "Left ventricular diastolic dysfunction" (ongoing), notes: last left ventr.
The patient's concomitant medications were not reported.
Vaccination history included: Covid-19 vaccine (DOSE 1, SINGLE; MANUFACTURER UNKNOWN), for COVID-19 immunisation; Covid-19 vaccine (DOSE 2, SINGLE; MANUFACTURER UNKNOWN), for COVID-19 immunisation; Covid-19 vaccine (DOSE 3 (BOOSTER), SINGLE; MANUFACTURER UNKNOWN), for COVID-19 immunisation.
The following information was reported: CARDIAC DEATH (death) with onset 12Feb2022, outcome "fatal", described as "acute cardiac death on 15Feb2022"; DYSPNOEA (death) with onset 12Feb2022, outcome "fatal", described as "shortness of breath as early as the day after the vaccination"; INCORRECT DOSE ADMINISTERED (death) with onset 11Feb2022, outcome "fatal", described as "Inappropriate dose of Vaccine administered".
The patient underwent the following laboratory tests and procedures: ejection fraction: 8.
21 at 28.
The patient date of death was 15Feb2022.
The reported cause of death was cardiac death.
It was not reported if an autopsy was performed.
Relatedness of the drug to the events: Cardiac death was reported as D: unclassifiable by the regulatory authority.
Sender Comment: Do you or the person concerned have any known allergies? If yes, which? no Clinical course: extended walks > 1 km possible, unchanged and persistent.
It was reported the onset of death is more likely to be based on the underlying disease, coronary Heart disease, dilated cardiomyopathy near.
No follow-up attempts are possible.
No further information is expected.
; Reported Cause(s) of Death: Cardiac death